On Friday, the Affimed NV (NASDAQ: AFMD) stock went on a strong rally after the company made a major announcement with regards to one of its products.
The company released the clinical data from the investigatory sponsored study a concoction in which Affirmed’s cell engager product AFM 13 had also been added. The study was conducted on patients who suffer from recurrent/refractory CD30-positive lymphomas. The data from the study proved to be positive and that was the reason behind the rally in the stock on Friday.
The Affimed stock climbed by as high as 23.50% on the back of the positive data from the study and it now remains to be seen if it can continue to add to its gains on Monday. The four patients who had been part of the study demonstrated a significant reduction in the disease. On top of that, two of the patients showed complete responses while the other two showed partial responses.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.